The maintenance of seizure control over time is a clinical priority in patients with epilepsy. The aim of this study was to assess the sustained seizure frequency reduction with adjunctive brivaracetam (BRV) in real-world practice. Patients with focal epilepsy prescribed add-on BRV were identified. Study outcomes included sustained seizure freedom and sustained seizure response, defined as a 100% and a ≥50% reduction in baseline seizure frequency that continued without interruption and without BRV withdrawal through the 12-month follow-up. Nine hundred ninety-four patients with a median age of 45 (interquartile range = 32–56) years were included. During the 1-year study period, sustained seizure freedom was achieved by 142 (14.3%) patients, of whom 72 (50.7%) were seizure-free from Day 1 of BRV treatment. Sustained seizure freedom was maintained for ≥6, ≥9, and 12 months by 14.3%, 11.9%, and 7.2% of patients from the study cohort. Sustained seizure response was reached by 383 (38.5%) patients; 236 of 383 (61.6%) achieved sustained ≥50% reduction in seizure frequency by Day 1, 94 of 383 (24.5%) by Month 4, and 53 of 383 (13.8%) by Month 7 up to Month 12. Adjunctive BRV was associated with sustained seizure frequency reduction from the first day of treatment in a subset of patients with uncontrolled focal epilepsy.
Sustained seizure freedom with adjunctive brivaracetam in patients with focal onset seizures / Lattanzi, Simona; Ascoli, Michele; Canafoglia, Laura; Paola Canevini, Maria; Casciato, Sara; CERULLI IRELLI, Emanuele; Chiesa, Valentina; Dainese, Filippo; De Maria, Giovanni; Didato, Giuseppe; DI GENNARO, Giancarlo; Falcicchio, Giovanni; Fanella, Martina; Gangitano, Massimo; La Neve, Angela; Mecarelli, Oriano; Montalenti, Elisa; Morano, Alessandra; Piazza, Federico; Pizzanelli, Chiara; Pulitano, Patrizia; Ranzato, Federica; Rosati, Eleonora; Tassi, Laura; DI BONAVENTURA, Carlo. - In: EPILEPSIA. - ISSN 0013-9580. - (2022). [10.1111/epi.17223]
Sustained seizure freedom with adjunctive brivaracetam in patients with focal onset seizures
Sara Casciato;Emanuele Cerulli Irelli;Giancarlo Di Gennaro;Martina Fanella;Oriano Mecarelli;Alessandra Morano;Patrizia Pulitano;Carlo Di Bonaventura
2022
Abstract
The maintenance of seizure control over time is a clinical priority in patients with epilepsy. The aim of this study was to assess the sustained seizure frequency reduction with adjunctive brivaracetam (BRV) in real-world practice. Patients with focal epilepsy prescribed add-on BRV were identified. Study outcomes included sustained seizure freedom and sustained seizure response, defined as a 100% and a ≥50% reduction in baseline seizure frequency that continued without interruption and without BRV withdrawal through the 12-month follow-up. Nine hundred ninety-four patients with a median age of 45 (interquartile range = 32–56) years were included. During the 1-year study period, sustained seizure freedom was achieved by 142 (14.3%) patients, of whom 72 (50.7%) were seizure-free from Day 1 of BRV treatment. Sustained seizure freedom was maintained for ≥6, ≥9, and 12 months by 14.3%, 11.9%, and 7.2% of patients from the study cohort. Sustained seizure response was reached by 383 (38.5%) patients; 236 of 383 (61.6%) achieved sustained ≥50% reduction in seizure frequency by Day 1, 94 of 383 (24.5%) by Month 4, and 53 of 383 (13.8%) by Month 7 up to Month 12. Adjunctive BRV was associated with sustained seizure frequency reduction from the first day of treatment in a subset of patients with uncontrolled focal epilepsy.File | Dimensione | Formato | |
---|---|---|---|
Lattanzi S Sustained seizure freedom with BRV Epilepsia 2022.pdf
accesso aperto
Note: Lattanzi_Sustained seizure freedom_2022
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Creative commons
Dimensione
1.26 MB
Formato
Adobe PDF
|
1.26 MB | Adobe PDF | Visualizza/Apri PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.